Maurice Wilkins Centre investigators across New Zealand lead a strong tuberculosis (TB) research programme that spans a range of subthemes - from learning about new target molecules within the TB organism to developing newer, more effective drugs.
The emergence and rapid spread of drug-resistant strains of Mycobacterium tuberculosis pose a grave threat to the effectiveness of TB treatment worldwide. Factored in with the ongoing HIV pandemic, it’s not surprising that the global incidence of TB remains high.
Investigators at the Maurice Wilkins Centre have been focusing their efforts on developing a new generation of anti-TB drugs, particularly those targeting energy generation. Over the next few years, we will be testing the most promising new drugs in human trials as well as newly discovered compounds in preclinical studies.